Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9983599 | 0.86 | ALDH1A1 (0.49) | KDM4EEGLN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL244112 | 0.84 | EGLN1 (0.68) | KDM4EEGLN1ALDH1A1 | |
| SCHEMBL8139304 | 0.84 | KDM4E (0.56) | KDM4EEGLN1ALDH1A1SLC40A1LMNA | |
| SCHEMBL12020192 | 0.83 | KDM4E (0.55) | KDM4EEGLN1ALDH1A1SLC40A1MAP2K1 | |
| SCHEMBL25985620 | 0.83 | KDM4E (0.55) | KDM4EEGLN1ALDH1A1SLC40A1MAP2K1 | |
| SCHEMBL344528 | 0.82 | ALDH1A1 (0.65) | KDM4EEGLN1ALDH1A1SLC40A1LMNA | |
| SCHEMBL644794 | 0.82 | ALDH1A1 (0.68) | KDM4EEGLN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL13943232 | 0.82 | ALDH1A1 (0.54) | KDM4EEGLN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL643192 | 0.80 | ALDH1A1 (0.46) | KDM4EEGLN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL16131034 | 0.80 | SLC40A1 (0.53) | KDM4EEGLN1ALDH1A1SLC40A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024130095-A9 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2017160670-A1 | M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017160670-A1 | M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | WO | disclosed |
| EP-2582241-B1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2582241-B1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-04-06 | — | — | EP | disclosed |
| US-8557992-B2 | Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557992-B2 | Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557992-B2 | Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130116272-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-05-09 | — | — | US | disclosed |
| US-20130116272-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-05-09 | — | — | US | disclosed |
| US-20130116272-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-05-09 | — | — | US | disclosed |
| EP-2582241-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011159553-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159553-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-22 | — | — | WO | disclosed |
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-2096109-A1 | CARBOXYLIC ACID DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-2096109-A1 | CARBOXYLIC ACID DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116272-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | KDM4E 1407/4885EGLN1 2688/4885ALDH1A1 2622/4885 |
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | GPR119, GPR65, HCAR1 | KDM4E 2414/4885EGLN1 2231/4885ALDH1A1 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.